By Colin Kellaher

Shares of Revance Therapeutics Inc. jumped more than 40% on Monday after the biotechnology company reported a pair of positive developments for its Daxxify antiwrinkle treatment.

The Nashville company on Monday reported preliminary fourth-quarter Daxxify revenue of $10.5 million to $11.5 million from PrevU, an early experience program Revance launched in support of the drug, which the Food and Drug Administration approved in September as a potential challenger to date to AbbVie Inc.’s market leading Botox.
Revance said it is confident in its commercial strategy for Daxxify, with a full-scale launch slated to begin late in the first quarter or early in the second quarter.
Separately, Revance late Friday said the FDA accepted its application seeking expanded approval of Daxxify for the treatment of adults with cervical dystonia, a chronic neurologic condition that affects the neck muscles.
The agency set a target action date of Aug. 19 for the application.
Revance shares were recently changing hands at $28.31, up nearly 44%.
Write to Colin Kellaher at colin.kellaher@wsj.com